Patents by Inventor Zhenquiang Lu

Zhenquiang Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular malignancy in melanocytic lesions
    Patent number: 9758829
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: September 12, 2017
    Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
  • SUBTYPING LUNG CANCERS
    Publication number: 20160019337
    Abstract: This disclosure concerns the identification of biomarkers that are characteristic of squamous or non squamous (e.g., adenocarcinoma, large cell carcinoma, carcinoid tumor, sarcomatoid carcinoma) subtypes of non small cell lung cancer (NSCLC), clinically useful NSCLC classifiers, kits and arrays for distinguishing squamous and nonsquamous NSCLC subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing.
    Type: Application
    Filed: March 3, 2014
    Publication date: January 21, 2016
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Christopher Roberts, Hui Wang, Zhenquiang Lu, Krishna Maddula, Sam Rua, Kevin Knapp, Byron Lawson, Debrah Thompson, Michael Hrubiak, Tyler Breedlove, Vijay Modur
  • MOLECULAR MALIGNANCY IN MELANOCYTIC LESIONS
    Publication number: 20150176072
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Application
    Filed: June 24, 2013
    Publication date: June 25, 2015
    Applicants: HTG Molecular Diagnostics, INc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Justin Brown, Tom Vasicek, BJ Kerns, Bruce E. Seligmann, Dave S.B. Hoon